Consensus QA improved target delineation for perihilar cholangiocarcinoma SBRT
Target Dice improved from 0.57 to 0.74 after consensus QA, although OAR constraints still limited PTV coverage in most plans.
Target Dice improved from 0.57 to 0.74 after consensus QA, although OAR constraints still limited PTV coverage in most plans.
An iridium-192 boost increased median progression-free survival from 8.6 to 11.2 months, without a significant overall-survival improvement.